Isomorphic Labs, headquartered in London, England, is revolutionizing the field of drug discovery using its AI-based platform. Recently, the company secured $600 million in a funding round, marking its first external capital raise.
This investment will bolster its capabilities in utilizing AI models, such as AlphaFold, to predict protein structures and enhance drug design processes.
Founded by Demis Hassabis, it operates as a spin-off from Alphabet’s DeepMind, underscoring its innovative approach to developing new therapies efficiently.
Leave a Reply